← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Lanreotide

FDA approved · Rx

Somatostatin analog

Also known as: Somatuline Depot, Lanreotide Acetate, Ipstyl, Lanreotida, Lanreotidum, Lanreotide Autogel, BIM 23014, Bim-23014, DC 13-116

Evidence score
95/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 118 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Lanreotide is a synthetic cyclic peptide that mimics the natural hormone somatostatin. It binds mainly to somatostatin receptors 2 and 5, which reduces the release of growth hormone and several gut hormones and can slow the growth of certain neuroendocrine tumors.

What the evidence shows

Automatic summaryHuman trials

Lanreotide is FDA-approved for acromegaly, gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome, supported by more than 100 registered human trials reaching Phase 4 and over 1,200 published papers. Uses outside these approved indications are less well established.

Key facts

Molecular formula
C54H69N11O10S2
Molecular weight
1096.3 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

118registered studies
Phase 4most advanced phase
62completed (sample)
5recruiting (sample)

Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

Phase 2WithdrawnNCT00517491

Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

Phase 3RecruitingNCT06878664

Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer

Phase 3CompletedNCT00630695

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

Phase 3RecruitingNCT06807437

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

1,258papers referencing Lanreotide

Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

N Engl J Med2014

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use.

Eur J Nucl Med2000

Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands.

Eur J Nucl Med2001

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.

Ann Oncol2004

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.